3,802 Shares of Danaher Corporation $DHR Bought by Meridian Investment Counsel Inc.

Meridian Investment Counsel Inc. purchased a new position in shares of Danaher Corporation (NYSE:DHR) during the third quarter, Holdings Channel reports. The firm purchased 3,802 shares of the conglomerate’s stock, valued at approximately $842,000.

Several other large investors also recently bought and sold shares of DHR. Marquette Asset Management LLC raised its holdings in Danaher by 192.1% in the 3rd quarter. Marquette Asset Management LLC now owns 111 shares of the conglomerate’s stock valued at $25,000 after acquiring an additional 73 shares during the last quarter. N.E.W. Advisory Services LLC purchased a new position in Danaher in the 2nd quarter worth approximately $25,000. Main Street Group LTD acquired a new stake in shares of Danaher in the first quarter valued at approximately $25,000. Field & Main Bank acquired a new stake in shares of Danaher in the second quarter valued at approximately $29,000. Finally, Evolution Wealth Management Inc. increased its holdings in shares of Danaher by 208.0% in the first quarter. Evolution Wealth Management Inc. now owns 154 shares of the conglomerate’s stock valued at $29,000 after purchasing an additional 104 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Key Danaher News

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

Danaher Stock Performance

NYSE:DHR opened at $224.65 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.65 and a quick ratio of 1.25. The firm has a market capitalization of $157.93 billion, a price-to-earnings ratio of 39.90, a PEG ratio of 2.80 and a beta of 0.76. The company’s 50-day moving average is $212.92 and its two-hundred day moving average is $195.39. Danaher Corporation has a 1-year low of $160.93 and a 1-year high of $242.80.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Monday, July 20th. The conglomerate reported $1.94 earnings per share for the quarter, beating the consensus estimate of $1.85 by $0.09. The business had revenue of $6.26 billion during the quarter, compared to analysts’ expectations of $6.12 billion. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The business’s revenue for the quarter was up 5.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.77 EPS. Analysts forecast that Danaher Corporation will post 8.53 EPS for the current year.

Danaher Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be issued a $0.40 dividend. The ex-dividend date is Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio is currently 28.42%.

Analyst Ratings Changes

A number of equities analysts recently commented on DHR shares. Evercore reiterated an “outperform” rating and set a $230.00 price objective on shares of Danaher in a research report on Monday, July 6th. Stifel Nicolaus dropped their target price on Danaher from $260.00 to $220.00 and set a “buy” rating for the company in a report on Wednesday, July 22nd. Royal Bank Of Canada upped their target price on Danaher from $215.00 to $250.00 and gave the company an “outperform” rating in a report on Monday, October 5th. Weiss Ratings raised Danaher from a “hold (c-)” rating to a “hold (c)” rating in a research note on Wednesday, September 16th. Finally, Guggenheim lifted their price target on Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Two investment analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $235.41.

Danaher Profile

Danaher Corporation (NYSE: DHR) is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.